Novo Nordisk A/S (NVO)vsMolson Coors Brewing Co Class B (TAP)
NVO
Novo Nordisk A/S
$46.07
+0.59%
HEALTHCARE · Cap: $202.85B
TAP
Molson Coors Brewing Co Class B
$42.41
-1.67%
CONSUMER DEFENSIVE · Cap: $8.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 2830% more annual revenue ($327.80B vs $11.19B). NVO leads profitability with a 37.2% profit margin vs -18.9%. TAP appears more attractively valued with a PEG of 4.23. NVO earns a higher WallStSmart Score of 74/100 (B).
NVO
Strong Buy74
out of 100
Grade: B
TAP
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NVO.
Margin of Safety
+59.8%
Fair Value
$132.44
Current Price
$42.41
$90.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Reasonable price relative to book value
Earnings expanding 35.6% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
2.0% revenue growth
Expensive relative to growth rate
ROE of -18.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bull Case : TAP
The strongest argument for TAP centers on Price/Book, EPS Growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Bear Case : TAP
The primary concerns for TAP are Revenue Growth, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
NVO profiles as a growth stock while TAP is a turnaround play — different risk/reward profiles.
TAP carries more volatility with a beta of 0.44 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (74/100 vs 56/100), backed by strong 37.2% margins and 24.0% revenue growth. TAP offers better value entry with a 59.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Molson Coors Brewing Co Class B
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
The Molson Coors Beverage Company, commonly known as Molson Coors, is a multinational drink and brewing company headquartered in Chicago in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?